Dare bioscience, inc. (DARE)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue

-

-

-

-

-

80

6

625

Operating expenses
General and administrative

5,265

4,655

2,704

157

11,224

8,587

6,166

6,393

Research and development

8,546

6,413

984

72

25,948

11,772

9,700

15,807

License Fee

533

625

0

400

-

-

-

-

Impairment of goodwill

0

5,187

7,500

-

-

-

-

-

Total operating expenses

14,344

16,882

11,180

630

37,172

20,359

15,866

22,200

Loss from operations

-14,344

-16,882

-11,180

-630

-

-

-

-

Interest income

-

-

-

-

10

9

2

2

Interest expense

-

-

-

42

2,432

1,083

1,487

567

Loss on extinguishment of debt

-

-

-

-

-

-2,493

-

-

Decrease in value of preferred stock warrant liability

-

-

-

-

-

-504

-202

-39

Other income

81

143

-322

-

-

-

-

-526

Total other expense, net

-

-

-

-

-2,422

-3,063

-1,283

-

Net loss

-14,263

-16,738

-11,503

-672

-39,594

-23,342

-17,143

-22,101

Deemed dividend from trigger of round down provision feature

789

0

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

73

Net loss to common shareholders

-15,053

-16,738

-

-

-

-

-

-22,174

Foreign currency translation adjustments

-5

-78

-18

-

-

-

-

-

Comprehensive loss

-15,059

-16,817

-11,521

-672

-

-

-

-

Loss per common share - basic and diluted (in usd per share)

-0.97

-1.57

3.56

-0.81

-1.56

-1.60

-25.05

-36.39

Weighted average number of common shares outstanding:
Basic

-

-

-

835

-

-

-

-

Diluted

-

-

-

835

-

-

-

-

Basic and diluted (in shares)

15,578

10,732

3,232

-

25,431

14,548

684

609